ARCA biopharma (ABIO)
(Delayed Data from NSDQ)
$3.58 USD
+0.10 (2.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.54 -0.04 (-1.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ABIO 3.58 +0.10(2.87%)
Will ABIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ABIO
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
Biotech Alert: Searches spiking for these stocks today
ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024
ARCA biopharma GAAP EPS of -$0.14
Arca Biopharma Increases Executive Retention Bonuses